服务平台拥有丰富的技术服务经验，一流的仪器设备，先进的检测手段和严格的质量控制体系，力求为全球药物研发机构提供优质高效的技术服务
背景介绍 TW-37 is a Bcl-2 inhibitor that has been shown to inhibit the angiogenic potential of endothelial cells in vitro. S-phase arrest and apoptosis in pancreatic cancer cell lines have been observed to be induced by TW-37. It binds to the Bcl-2 homology domain 3 (BH3) groove of Bcl-2 preventing the heterodimerization of proapoptotic proteins (such as Bid, Bim, and Bad) with Bcl-2 and subsequently allowing them to induce apoptosis. Recent studies indicate TW-37 is able to inhibit the growth of a broad range of cancer cells (such as breast, prostate, lymphoma, and pancreatic cancer), since it induces S-phase cell cycle arrest with regulation of several important cell cycle related genes, including p27, p57, E2F-1, cdc25A, CDK4, cyclin A, cyclin D1 and cyclin E. 产品介绍 TW-37 is a potent small-molecule inhibitor that attenuates Bcl-2 activation and inhibits multiple Bcl-2 family members including Bcl-xL and Mcl-1. TW-37 also inhibits in vivo and in vitro the activation of Jagged-1 and Notch-1.
询价背景介绍 TW-37 is a Bcl-2 inhibitor that has been shown to inhibit the angiogenic potential of endothelial cells in vitro. S-phase arrest and apoptosis in pancreatic cancer cell lines have been observed to be induced by TW-37. It binds to the Bcl-2 homology domain 3 (BH3) groove of Bcl-2 preventing the heterodimerization of proapoptotic proteins (such as Bid, Bim, and Bad) with Bcl-2 and subsequently allowing them to induce apoptosis. Recent studies indicate TW-37 is able to inhibit the growth of a broad range of cancer cells (such as breast, prostate, lymphoma, and pancreatic cancer), since it induces S-phase cell cycle arrest with regulation of several important cell cycle related genes, including p27, p57, E2F-1, cdc25A, CDK4, cyclin A, cyclin D1 and cyclin E. 产品介绍 TW-37 is a potent small-molecule inhibitor that attenuates Bcl-2 activation and inhibits multiple Bcl-2 family members including Bcl-xL and Mcl-1. TW-37 also inhibits in vivo and in vitro the activation of Jagged-1 and Notch-1.
询价背景介绍 TW-37 is a Bcl-2 inhibitor that has been shown to inhibit the angiogenic potential of endothelial cells in vitro. S-phase arrest and apoptosis in pancreatic cancer cell lines have been observed to be induced by TW-37. It binds to the Bcl-2 homology domain 3 (BH3) groove of Bcl-2 preventing the heterodimerization of proapoptotic proteins (such as Bid, Bim, and Bad) with Bcl-2 and subsequently allowing them to induce apoptosis. Recent studies indicate TW-37 is able to inhibit the growth of a broad range of cancer cells (such as breast, prostate, lymphoma, and pancreatic cancer), since it induces S-phase cell cycle arrest with regulation of several important cell cycle related genes, including p27, p57, E2F-1, cdc25A, CDK4, cyclin A, cyclin D1 and cyclin E. 产品介绍 TW-37 is a potent small-molecule inhibitor that attenuates Bcl-2 activation and inhibits multiple Bcl-2 family members including Bcl-xL and Mcl-1. TW-37 also inhibits in vivo and in vitro the activation of Jagged-1 and Notch-1.
询价背景介绍 The serine/threonine Pim kinases have been suggested to promote the activity of the rapamycin-sensitive mammalian target of rapamycin (mTORC1), which regulates cell growth and survival. Pim kinases are overexpressed in solid cancers and hematologic malignancies, and as such have become targets of small molecule inhibitors to prevent the progression of various cancers. SIM-4a is a Pim kinase inhibitor that blocks mTORC1 activity via activation of AMPK.1 SMI-4a has been found to inhibit prostate cancer cell growth and induce G1 phase cell-cycle arrest in precursor T-cell lymphoblastic leukemia/lymphoma cell lines. 产品介绍 SMI-4a is a potent inhibitor of Pim1 with IC50 = 17 -21 nM. It does not significantly inhibit other serine/threonine- or tyrosine-kinases. It induces G1 phase cell cycle arrest and induces apoptosis through the mitocondrial pathway. It downregulates c-myc and induces p27Kip1 expression. Inhibits PRAS40 phosphorylation and mTOR activity, as well as the mammalian target of rapamycin C1 (mTORC1) pathway. SMI-4a is a potential anti-cancer compound that blocks prostate cancer growth.
询价背景介绍 The serine/threonine Pim kinases have been suggested to promote the activity of the rapamycin-sensitive mammalian target of rapamycin (mTORC1), which regulates cell growth and survival. Pim kinases are overexpressed in solid cancers and hematologic malignancies, and as such have become targets of small molecule inhibitors to prevent the progression of various cancers. SIM-4a is a Pim kinase inhibitor that blocks mTORC1 activity via activation of AMPK.1 SMI-4a has been found to inhibit prostate cancer cell growth and induce G1 phase cell-cycle arrest in precursor T-cell lymphoblastic leukemia/lymphoma cell lines. 产品介绍 SMI-4a is a potent inhibitor of Pim1 with IC50 = 17 -21 nM. It does not significantly inhibit other serine/threonine- or tyrosine-kinases. It induces G1 phase cell cycle arrest and induces apoptosis through the mitocondrial pathway. It downregulates c-myc and induces p27Kip1 expression. Inhibits PRAS40 phosphorylation and mTOR activity, as well as the mammalian target of rapamycin C1 (mTORC1) pathway. SMI-4a is a potential anti-cancer compound that blocks prostate cancer growth.
询价背景介绍 Pracinostat (SB939) is an orally bioavailable, small-molecule histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Pracinostat inhibits HDACs, which may result in the accumulation of highly acetylated histones. It is a pan-HDAC inhibitor, inhibiting all HDAC isozymes except HDAC6 and HDAC7. 产品介绍 Potent and oral inhibitor of histone deacetylase (HDAC), selective for class I, II and IV HDACs. SB939 shows significant antiproliferative activity against a wide variety of tumor cell lines, with high tumor exposure and efficacy in mouse models of colorectal cancer.
询价背景介绍 Pracinostat (SB939) is an orally bioavailable, small-molecule histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Pracinostat inhibits HDACs, which may result in the accumulation of highly acetylated histones. It is a pan-HDAC inhibitor, inhibiting all HDAC isozymes except HDAC6 and HDAC7. 产品介绍 Potent and oral inhibitor of histone deacetylase (HDAC), selective for class I, II and IV HDACs. SB939 shows significant antiproliferative activity against a wide variety of tumor cell lines, with high tumor exposure and efficacy in mouse models of colorectal cancer.
询价背景介绍 Pracinostat (SB939) is an orally bioavailable, small-molecule histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Pracinostat inhibits HDACs, which may result in the accumulation of highly acetylated histones. It is a pan-HDAC inhibitor, inhibiting all HDAC isozymes except HDAC6 and HDAC7. 产品介绍 Potent and oral inhibitor of histone deacetylase (HDAC), selective for class I, II and IV HDACs. SB939 shows significant antiproliferative activity against a wide variety of tumor cell lines, with high tumor exposure and efficacy in mouse models of colorectal cancer.
询价背景介绍 PCI-24781 is a pan-HDAC inhibitor that shows antitumor activity in vitro and in vivo preclinically and is under evaluation in phase I clinical trials for cancer, particularly B-cell lymphoma. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-?B mechanisms in Hodgkin lymphoma and non-Hodgkin lymphoma cell lines. 产品介绍 PCI-24781 (also known as CRA-024781) is a novel, broad spectrum inhibitor of HDACs that shows antitumor activity in vitro. PCI-24781 primarily targets HDAC1 (Ki = 7 nM). It also exhibits modest potenty toward HDACs 2, 3, 6, and 10 and greater than 40-fold selectivity against HDAC8.
询价
